Keytruda Lifecycle Moves Soften Cliff, but Rally Leaves Little Margin of Safety

What happened

Merck has aggressively extended Keytruda's commercial life with the subcutaneous Qlex formulation, securing an IP shield potentially into 2039, while recent acquisitions of Terns and Cidara broaden its late-stage oncology and virology pipeline. These steps have convinced some analysts that the post-2028 revenue hole looks less daunting, contributing to a 17% rally since the last quarterly update. However, the DeepValue master report maintains a WAIT rating, arguing that the stock now trades at a fair 13.5x 2030‑32 P/E, fully pricing in the improved outlook. Near‑term execution remains critical, with a $2.5 billion headwind in 2026 from generics and IRA pricing still looming, and Gardasil’s China shipment pause unresolved. The next 6–9 months will test whether new launches can offset that erosion, and without a clear restart signal from China, upside is limited.

Implication

Merck’s lifecycle engineering has indeed made the Keytruda cliff look less catastrophic, but the market has already rewarded that progress with a 17% run‑up. For new money, the entry point is less attractive, and existing holders should monitor near‑term checkpoints: the April 2026 FDA decision for a Keytruda‑related filing, closure of the Terns deal, and any sign that Gardasil shipments to China might resume. If these catalysts are positive without lifting guidance above the already‑anticipated $65.5–67.0B revenue range, the stock may struggle to break out. Conversely, any disappointment on the $2.5B headwind or a further China delay could trigger a pullback toward the $105 attractive entry zone identified in the report. At $119, the margin of safety is thin, and a WAIT posture is justified until we see the 2026 erosion bridge hold firm.

Thesis delta

The core thesis that MRK is a 2026 holding pattern waiting for diversification proof remains intact, but the narrative has shifted from fearing a sudden cliff to a more manageable, albeit still large, revenue step‑down. Management’s actions have extended Keytruda’s runway and added pipeline breadth, lowering the bear‑case risk. However, the recent rally has absorbed much of that improvement, refocusing the thesis on valuation discipline and the need for flawless execution in 2026.